Search PubMed⌕ Search

Biomedical subjects

I Gibb

Publications and source records attributed to I Gibb.

29 records · Page 2Linked to original sources
PubMed1984

Serum alpha fetoprotein heterogeneity as a means of differentiating between primary hepatocellular carcinoma and hepatic secondaries.

The concanavalin A binding characteristics of serum alpha-fetoprotein (AFP) were investigated in patients with primary hepatocellular carcinoma and hepatic secondaries using affinity column chromatography and radioimmunoassay. The primary hepatocellular carcinoma (n = 21) was associated with a median concanavalin A non-reactive AFP fraction of 7.4% (range 1.6 - 18.8) while the hepatic secondaries (n = 8) had a median concanavalin A non-reactive AFP fraction of 50.7% (range 26.6 - 91.7). A simple diagnostic test for differentiating between the two groups of patients is proposed.

Adolescent↗
PubMed1983

Plasma digoxin: assay anomalies in Fab-treated patients.

Using a variety of radioimmunoassay methods, plasma digoxin concentrations were measured in two patients before and after the administration of ovine Fab antibody fragments to remove the effects of digoxin. Gross method-dependent anomalies in the results due to in vitro drug interaction were observed. More widespread use of immunotherapy may invalidate data obtained by direct immunoassay techniques.

Digoxin↗
PubMed1983

Use of a recommended evaluation scheme in the assessment of a new digoxin radioimmunoassay kit.

A new digoxin radioimmunoassay kit with a magnetizable solid-phase antibody was assessed using a recommended evaluation scheme. The kit was found to have acceptable performance characteristics, and the results are presented in the format recommended in the evaluation scheme to maximize comparability with data from other such studies. While the evaluation protocol was found to be generally workable and valid, modifications are suggested to enhance its applicability to an immunoassay system.

Digoxin↗
PubMed1981

Prophylactic oral methotrexate therapy for multiple superficial bladder carcinoma.

Sixteen patients with multiple, frequently recurring Ta/T1 transitional cell carcinoma of the bladder were treated with methotrexate syrup 50 mg orally every week, for 18 months. In 11 patients the frequency, number and size of tumour recurrences decreased markedly. In 3 patients the incidence of tumour recurrence appeared unchanged and in 2 patients the disease progressed and required cystectomy. Overall, the average number of tumours recurring per patient month at risk fell significantly from 2.6 to 1.2 while taking methotrexate. It is suggested that oral methotrexate may provide an effective alternative to intravesical chemotherapy for the prevention of recurrent superficial bladder carcinoma.

Administration, Oral↗
PubMed1981

Oral methotrexate therapy for multiple superficial bladder carcinomata.

Patients with frequently recurring multiple class T1 bladder carcinomata have been treated with methotrexate (MTX) given as 50 mg in syrup every week. In 16 of 17 patients the frequency and number of tumor recurrences have been reduced. Measurement of MTX levels in the urine confirms that this dose of drug yields concentrations that are thought to be cytotoxic for at least 24 hours.

Administration, Oral↗